Modular Medical, INC. (MODD) — SEC Filings

Overview

Modular Medical, INC. (MODD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-3 filed on Apr 23, 2026: Modular Medical, Inc. filed an S-3 registration statement on April 23, 2026, to register an unspecified amount of securities. The filing includes a sales agreement dated April 23, 2026, between the company and Maxim Group LLC, indicating a potential offering. Legal opinions from Luccky Brookman LLP

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 5 bearish, 26 neutral. The dominant filing sentiment for Modular Medical, INC. is neutral.

Filing Type Overview

Modular Medical, INC. (MODD) has filed 1 S-3, 14 8-K, 6 10-Q, 2 10-K, 2 DEF 14A, 1 10-Q/A, 2 SC 13D/A, 1 SC 13G, 2 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (31)

• Modular Medical Files S-3 for Potential Securities Offering — S-3 · Apr 23, 2026 Risk: medium
  Modular Medical, Inc. filed an S-3 registration statement on April 23, 2026, to register an unspecified amount of securities. The filing includes a sales agreem
• Modular Medical Faces Delisting Concerns — 8-K · Dec 31, 2025 Risk: high
  Modular Medical, Inc. filed an 8-K on December 30, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The filing also include
• Modular Medical, Inc. Files 8-K with Material Agreement — 8-K · Dec 11, 2025 Risk: medium
  On December 10, 2025, Modular Medical, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements
• MODD's Losses Widen Amid R&D Surge; Cash Dwindles — 10-Q · Nov 14, 2025 Risk: high
  Modular Medical, Inc. (MODD) reported a significant increase in net loss for the three and six months ended September 30, 2025, primarily driven by increased op
• Modular Medical Files 8-K: Material Agreement & Equity Sales — 8-K · Sep 23, 2025 Risk: medium
  On September 22, 2025, Modular Medical, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
• Modular Medical's Losses Widen Amid R&D Surge, Cash Drains — 10-Q · Aug 14, 2025 Risk: high
  Modular Medical, Inc. (MODD) reported a net loss of $6.702 million for the three months ended June 30, 2025, a significant increase from the $4.137 million net
• Modular Medical Faces Delisting Concerns — 8-K · Jul 2, 2025 Risk: high
  Modular Medical, Inc. filed an 8-K on July 2, 2025, reporting a notice of delisting or failure to satisfy continued listing rules as of June 30, 2025. The compa
• Modular Medical's Losses Widen Amid Insulin Pump Development Push — 10-K · Jun 20, 2025 Risk: high
  Modular Medical, Inc. (MODD) reported no revenue for the fiscal year ended March 31, 2025, consistent with its pre-commercialization stage as a medical device c
• Modular Medical Appoints New Directors and CMO — 8-K · May 28, 2025 Risk: medium
  On May 22, 2025, Modular Medical, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, including Dr. Davi
• Modular Medical Enters Material Agreement, Files 8-K — 8-K · Mar 26, 2025 Risk: medium
  On March 20, 2025, Modular Medical, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
• Modular Medical Files 8-K on Shareholder Votes and Financials — 8-K · Mar 3, 2025 Risk: low
  Modular Medical, Inc. filed an 8-K on February 28, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing detai
• Modular Medical Files Q3 2024 10-Q — 10-Q · Feb 13, 2025 Risk: low
  Modular Medical, Inc. filed its 10-Q for the quarterly period ended December 31, 2024. The company, incorporated in Nevada, operates in the surgical and medical
• Modular Medical Files Definitive Proxy Statement — DEF 14A · Jan 24, 2025 Risk: low
  Modular Medical, Inc. filed its definitive proxy statement on January 24, 2025, for its annual meeting of stockholders. The filing concerns the solicitation of
• Modular Medical Files 10-Q Amendment — 10-Q/A · Nov 27, 2024 Risk: medium
  Modular Medical, Inc. filed an amendment (Amendment No. 1) to its Form 10-Q for the quarterly period ended September 30, 2024. This filing is an update to their
• Modular Medical Secures $1.5M Loan — 8-K · Nov 25, 2024 Risk: medium
  On November 21, 2024, Modular Medical, Inc. entered into a Material Definitive Agreement, specifically a loan agreement with an affiliate of its principal stock
• Manchester Management Files 13D/A for Modular Medical — SC 13D/A · Nov 25, 2024 Risk: medium
  Manchester Management Co LLC, through James E. Besser, has amended its Schedule 13D filing for Modular Medical, Inc. as of November 21, 2024. The filing indicat
• Modular Medical Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: low
  Modular Medical, Inc. filed its 10-Q for the quarterly period ended September 30, 2024. The company, incorporated in Nevada, is involved in the surgical and med
• Modular Medical Appoints New CFO, Grants Stock Options — 8-K · Sep 5, 2024 Risk: medium
  On September 4, 2024, Modular Medical, Inc. filed an 8-K report detailing the appointment of Kevin L. Johnson as Chief Financial Officer, effective September 3,
• Modular Medical Elects New Directors, Two Resign — 8-K · Aug 27, 2024 Risk: low
  Modular Medical, Inc. announced on August 22, 2024, a change in its board of directors. Specifically, the company elected two new directors, Dr. David L. Smith
• Modular Medical Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Modular Medical, Inc. filed its 10-Q for the quarterly period ended June 30, 2024. The company, incorporated in Nevada, is involved in the surgical and medical
• Modular Medical Files 2024 Annual Report — 10-K · Jun 21, 2024 Risk: low
  Modular Medical, Inc. filed its annual report for the fiscal year ended March 31, 2024. The company, incorporated in Nevada, is involved in the surgical and med
• Modular Medical Appoints New CFO — 8-K · Apr 10, 2024 Risk: medium
  Modular Medical, Inc. announced on April 8, 2024, the appointment of Kevin McGlynn as Chief Financial Officer, effective immediately. McGlynn previously served
• SC 13G Filing — SC 13G · Mar 1, 2024
• Manchester Management Amends Modular Medical Stake — SC 13D/A · Feb 21, 2024 Risk: low
  Manchester Management Company, LLC, and James E. Besser filed an Amendment No. 7 to their Schedule 13D on February 21, 2024, regarding their ownership in Modula
• Modular Medical Files 8-K on Material Agreement — 8-K · Feb 16, 2024 Risk: medium
  Modular Medical, Inc. filed an 8-K on February 16, 2024, reporting an event that occurred on February 15, 2024. The filing indicates an entry into a material de
• Modular Medical Reports Security Holder Rights & Bylaw Changes — 8-K · Feb 15, 2024 Risk: medium
  Modular Medical, Inc. filed an 8-K on February 15, 2024, reporting events that occurred on February 13, 2024. The filing indicates material modifications to the
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Modular Medical, Inc. Files 10-Q for Period Ended December 31, 2023 — 10-Q · Feb 13, 2024 Risk: medium
  Modular Medical, Inc. (MODD) filed a Quarterly Report (10-Q) with the SEC on February 13, 2024. Modular Medical, Inc. filed its quarterly report (10-Q) for the
• Modular Medical Updates Principal Executive Office Address — 8-K · Jan 19, 2024
  Modular Medical, Inc. (MODD) filed an 8-K on January 19, 2024, to update its principal executive offices to 10740 Thornmint Road, San Diego, California 92127. T
• Modular Medical, Inc. Announces 2024 Annual Meeting of Shareholders — DEF 14A · Jan 8, 2024 Risk:
  Modular Medical, Inc. (MODD) filed a Proxy Statement (DEF 14A) with the SEC on January 8, 2024. Modular Medical, Inc. will hold its 2024 Annual Meeting of Share

Risk Profile

Risk Assessment: Of MODD's 26 recent filings, 5 were flagged as high-risk, 14 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Modular Medical, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Net Income: -$14.49M
• Cash Position: $5.32M

Key Executives

• Dr. David L. Smith
• Mr. David L. Smith
• principal stockholder
• James E. Besser
• Kevin L. Johnson
• Mr. Michael J. Collins
• David L. Smith
• Michael J. Collins
• Kevin McGlynn
• David Johnson
• Paul DiPerna

Industry Context

The medical device industry, particularly in diabetes management, is highly competitive and innovation-driven. Companies like Modular Medical are focused on developing advanced delivery systems, such as insulin pumps, to improve patient outcomes and convenience. Regulatory approvals, like FDA clearance, are critical gating items for market entry and commercial success.

Top Tags

10-Q (5) · material-agreement (4) · Medical Devices (3) · regulatory-filing (3) · financials (3) · corporate-governance (3) · medical-devices (3) · delisting (2) · listing-standards (2) · filing (2)

Key Numbers

• File Number: 333-295255 — Identifies this specific S-3 registration
• CIK: 0001074871 — Central Index Key for Modular Medical, Inc.
• Net Loss: $14.49M — for the six months ended September 30, 2025, up from $9.09M in 2024
• Cash and Cash Equivalents: $5.32M — as of September 30, 2025, down from $13.09M on March 31, 2025
• Research and Development Expenses: $10.73M — for the six months ended September 30, 2025, up from $6.91M in 2024
• Proceeds from Warrant Inducement Offering: $3.9M — received in September 2025
• Proceeds from At-the-Market Sales: $0.7M — for the six months ended September 30, 2025
• Outstanding Shares: 63.6M — as of November 12, 2025
• Selling, General and Administrative Expenses: $3.91M — for the six months ended September 30, 2025, up from $2.31M in 2024
• Net Cash Used in Operating Activities: $5.372M — Increased from $3.548M in Q1 2024, highlighting accelerated operational cash outflow.
• Common Shares Outstanding: 55,274,596 — As of August 8, 2025, indicating potential dilution from financing activities.
• Expected Initial Shipments: October 2025 — For the MODD1 pump, crucial for future revenue generation.
• Potentially Dilutive Securities (in thousands): 25,313 — As of June 30, 2025, indicating future dilution risk.
• Commission File Number: 001-41277 — Identifies the company's filing with the SEC.
• I.R.S. Employer Identification Number: 87-0620495 — Company's tax identification number.

Related Companies

MODL · PODD · TNDM

Frequently Asked Questions